Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

862
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
862
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Tissue Transplantation01:24

Tissue Transplantation

888
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
888

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine-mediated activation of kidney-infiltrating CD8<sup>+</sup> T cells enables their contribution to inflammation in human lupus nephritis.

Science translational medicine·2026
Same author

BCMA-directed therapy with cizutamig induces rapid improvement in long-standing systemic sclerosis-associated interstitial lung disease.

Rheumatology (Oxford, England)·2026
Same author

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Annals of the rheumatic diseases·2026
Same author

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.

Annals of the rheumatic diseases·2026
Same author

IgG4-related disease has a specific intestinal microbiota signature.

EBioMedicine·2026
Same author

Obexelimab for the Treatment of IgG4-Related Disease.

The New England journal of medicine·2026

Related Experiment Video

Updated: Jan 14, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

875

Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing

Richard K Burt1, Tobias Alexander2

  • 1Hematology Scripps Health, La Jolla, CA, United States; Northwestern University (retired) and Genani Biotech Corp, Chicago, IL, United States.

Handbook of Clinical Neurology
|January 12, 2026
PubMed
Summary

Autologous hematopoietic stem cell transplantation (HSCT) offers a drug-free improvement for multiple sclerosis (MS) patients. This immune-based therapy is most effective during the inflammatory stages of MS.

Keywords:
Hematopoietic stem cell transplantation (HSCT)Multiple sclerosis (MS)

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.1K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.7K

Related Experiment Videos

Last Updated: Jan 14, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

875
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.1K
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.7K

Area of Science:

  • Neurology
  • Immunology
  • Hematology

Background:

  • Autologous hematopoietic stem cell transplantation (HSCT) involves immunosuppression followed by stem cell infusion to restore blood cell production.
  • Nonmyeloablative HSCT regimens are safer for multiple sclerosis (MS) than traditional myeloablative approaches used in cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of autologous HSCT for multiple sclerosis (MS).
  • To compare HSCT outcomes against current disease-modifying therapies (DMTs) for MS.

Main Methods:

  • Administration of a short immunosuppressive regimen (4-6 days) followed by autologous stem cell infusion.
  • Patient selection and specific regimen protocols are critical determinants of HSCT toxicity and efficacy.

Main Results:

  • HSCT is most effective for the inflammatory phase of MS, including relapsing-remitting MS and active secondary progressive MS.
  • A Phase III randomized trial and meta-analyses show HSCT superiority over contemporary DMTs, including natalizumab.
  • HSCT leads to sustained, drug-free improvements in neurological disability and quality of life in most patients.

Conclusions:

  • Autologous HSCT represents a significant advancement in MS treatment, offering long-term benefits beyond conventional therapies.
  • The procedure's effectiveness is stage-dependent, highlighting its role in managing active inflammatory MS.
  • HSCT provides a valuable therapeutic option for MS patients, demonstrating superior long-term outcomes compared to DMTs.